Biologics CDMO opens new facility in Research Triangle

By Melissa Fassbender

- Last updated on GMT

The BioProcess Innovation Center in Research Triangle Park, North Carolina. (Image: FUJIFILM Diosynth Biotechnologies U.S.A., Inc.)
The BioProcess Innovation Center in Research Triangle Park, North Carolina. (Image: FUJIFILM Diosynth Biotechnologies U.S.A., Inc.)

Related tags Biotechnology Research triangle park Innovation

The BioProcess Innovation Center is a new three-story, 62,000 square foot facility in Research Triangle Park, North Carolina.

FUJIFILM Diosynth Biotechnologies U.S.A. officially opened the facility earlier this morning at a ribbon cutting ceremony attended by local government and biotech community members. 

The Contract Development and Manufacturing Organization (CDMO) focuses on developing and manufacturing recombinant biopharmaceuticals, including proteins, vaccines, and monoclonal antibodies.

The construction and completion of this building reflects the continued commitment of our organization to provide our clients with the infrastructure to efficiently and innovatively bring their products to the clinic and beyond for the benefit of their patients​,” said Steve Bagshaw, CEO, FUJIFILM Diosynth Biotechnologies.

The building houses the company’s Process and Analytical Research and Development, Process Sciences and Stability groups, which, according to the company, will focus on delivery process invention, design and development, and process and product characterization for its clients.

The groups will also continue to develop the company’s biomanufacturing systems and approaches.

The design of the facility reflects our core philosophy of cross-functional collaboration to Research and Process Development which is a key differentiator of our company​,” said Martin Meeson, President, FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars